CorMedix (CRMD) Cost of Revenue (2013 - 2026)

CorMedix has reported Cost of Revenue for 12 years, with the latest figure at $11.2 million in Q4 2025.

• Quarterly Cost of Revenue rose 894.52% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.2 million (up 619.16% YoY) and the FY2025 annual result came in at $22.1 million, up 628.05% from the prior year.
• Cost of Revenue advanced to $11.2 million in Q4 2025 per CRMD's latest filing, from $7.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $11.2 million in Q4 2025 and troughed at $332.0 in Q2 2022.
• A 4-year average of $1.6 million and a median of $285589.0 in 2021 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue sank 99.15% in 2022, then jumped 1092.16% in 2025.
• Over 4 years, Cost of Revenue stood at $48007.0 in 2021, then tumbled by 99.15% to $406.0 in 2022, then surged by 276481.53% to $1.1 million in 2024, then jumped by 894.52% to $11.2 million in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $11.2 million, $7.6 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.